Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27208041
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+Immunol
2016 ; 28
(7
): 365-70
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Targeting neoantigens for cancer immunotherapy
#MMPMID27208041
Lu YC
; Robbins PF
Int Immunol
2016[Jul]; 28
(7
): 365-70
PMID27208041
show ga
Studies first carried out in the 1980s have demonstrated murine T cells can
recognize mutated gene products, known as neoantigens, and that these T cells are
capable of mediating tumor rejection. The first human tumor antigens isolated in
the early 1990s were the products of non-mutated genes expressed in a
tissue-specific manner; subsequent studies have indicated that tumor-infiltrating
lymphocytes that are cultured in vitro frequently recognize mutated gene
products. In addition, correlative studies indicate that clinical responses to
therapies involving the use of antibodies directed against checkpoint inhibitors
such as CTLA-4 and PD-1 may be associated with mutational burden, providing
indirect evidence that these responses may primarily be mediated by
neoantigen-reactive T cells. The importance of neoantigen-reactive T cells may be
elucidated by the results of ongoing and future studies aimed at leveraging
information gained from mutational profiling to enhance the potency of
immunotherapies.
|Animals
[MESH]
|Antibodies, Monoclonal/*therapeutic use
[MESH]
|Antigens, Neoplasm/immunology
[MESH]
|CTLA-4 Antigen/immunology
[MESH]
|Cancer Vaccines/*immunology
[MESH]
|Humans
[MESH]
|Immunotherapy/*methods
[MESH]
|Neoplasms/immunology/*therapy
[MESH]
|Programmed Cell Death 1 Receptor/immunology
[MESH]
free
free
free
